Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm

Husayn Ahmed Pallikonda; Samra Turajlic

doi:10.1016/j.bbcan.2022.188759

Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm

Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188759. doi: 10.1016/j.bbcan.2022.188759. Epub 2022 Jul 11.

Authors

Husayn Ahmed Pallikonda¹, Samra Turajlic²

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London, United Kingdom.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London, United Kingdom; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Melanoma and Kidney Cancer Team, Institute of Cancer Research, London, United Kingdom. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 35835341
DOI: 10.1016/j.bbcan.2022.188759

Abstract

Evolutionary features of cancer have important clinical implications, but their evaluation in the clinic is currently limited. Here, we review current approaches to reconstruct tumour subclonal structure and discuss tumour sampling method and experimental design influence. We describe clear-cell renal cell carcinoma (ccRCC) as an exemplar for understanding and predicting cancer evolutionary dynamics. Finally, we discuss how understanding cancer evolution can benefit patients.

Keywords: Cancer dynamics; Cancer evolution; Clear cell renal cell carcinoma; Patient benefit; Patient management; Representative sequencing; Subclonal reconstruction.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Carcinoma, Renal Cell* / genetics
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / genetics
Kidney Neoplasms* / pathology

Abstract

Publication types

MeSH terms

Grants and funding